Cover Image
市場調查報告書

癌症治療的生技仿製藥的利用:關鍵意見領袖(KOL)的考察

Biosimilars in Oncology: KOL Insight

出版商 FirstWord 商品編碼 351855
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療的生技仿製藥的利用:關鍵意見領袖(KOL)的考察 Biosimilars in Oncology: KOL Insight
出版日期: 2016年01月01日 內容資訊: 英文
簡介

強烈的生存意識、在生死狹縫間決定治療方針的癌症專門醫師之間,至今尚未認同生技仿製藥為確實的治療藥。

本報告提供癌症治療上生技仿製藥利用的關鍵意見領袖(KOL)見解之調查,驗証証據的品質,成本,配合患者,治療環境等阻礙引進、利用的各種課題。

調查課題

  • 証據的品質:應該克服的門檻
    • 生技仿製藥可利用的証據相關之KOL的疑慮
  • 超過成本問題的患者相關課題
    • 透過實證成果支配治療的選擇
  • 存活率資料支配思考
    • 為何癌症專門醫生重視對照製劑的比較?
  • 治療環境的重要性
    • 生技仿製藥的利用·引進的見解會依環境而不同嗎?
  • 資訊發現的困難
    • 為何在主要醫療日誌的資訊如此之少?
    • 今後是否會改善?
  • 參加優先級低的臨床實驗
    • 妨礙癌症專門醫生參加有可能得到極其重要証據之臨床實驗的要素為何?
  • 處方者和保險者的衝突
    • 處方者和保險者的衝突將如何排解?
  • 引進率
    • 什麼時候腫瘤部門生技仿製藥能更進一步普及?
    • 推遲這個的其他因素是什麼?
目錄
Product Code: 596200448

Will physicians ever adopt Biosimilars in Oncology?

Sceptical, survival focussed oncologists that make treatment decisions in life or death situations aren't yet ready to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets?

Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current challenges from 12 leading North American and European KOLs. Understand what you need to do to convince oncologists to use biosimilars.

"Cost, cost, cost. It's the one and only driver of biosimilar usage in the US." - US key opinion leader

Answering key questions about oncology biosimilars

  • Quality of evidence is a hurdle to overcome: What's worrying KOLs about the evidence available for biosimilars?
  • Patient concerns outweigh cost issues: Why do proven results govern treatment choices every time?
  • Survival data issues dominate thinking: Why are comparisons with reference products seen as essential by oncologists?
  • Treatment setting is a factor: Are there different views on the use and take-up of biosimilars for supportive care v the treatment space?
  • Information is hard to find: Why is so little published in key medical journals and is this likely to improve?
  • Participation in trials is a low priority: What's holding back participation in trials that could produce the conclusive evidence oncologists badly want?
  • Conflict between prescribers and payers set to continue: How are conflicts between payers and prescribers likely to be resolved?
  • Adoption rates: How soon will it be before biosimilars are used more widely in oncology and what other factors are holding this back?

Top takeaways

  • Conflicting pressures on biosimilar adoption: Oncologists are resisting moves to drive down costs from payers despite increasing treatment outlay
  • Oncologists have specific needs: Pharma companies need to understand exactly what evidence is needed to convince physicians to use biosimilar treatments
  • More education wanted: The vast majority of physicians want more education on biosimilars both from companies and as continuing medical education
  • EU and US at odds over naming conventions and labelling: There are concerns over confusion and traceability in product names
  • Biosimilar awareness growing: Awareness is higher in Europe than the US although this is improving with the recent launch of Zarxio (Sandoz)
  • Prompt action is needed: Given the time it takes to reach the market, pharma companies need to make sure evidence issues are addressed early

Key issues explored

  • An in-depth summary of the oncology biosimilars landscape, including details of several high profile late-stage programmes
  • The oncology products that biosimilars are targeting
  • The economic burden of cancer and the potential solutions biosimilars could offer
  • Barriers and drivers for biosimilar adoption in the oncology setting
  • Whether oncologists understand the technical, clinical and regulatory aspects of biosimilars
  • The likely adoption rates for key therapeutic monoclonal antibodies (mAbs)

A report based on expert knowledge

KOLs from the US

  • Joshua Brody: Assistant Professor of Medicine, Haematology and Medical Oncology, Mount Sinai Hospital, New York, NY.
  • Young Kwang Chae: Assistant Professor in Medicine, Haematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Thai H. Ho: Medical Oncologist, Mayo Clinic, Scottsdale, AZ.
  • Philip Lammers: Chief of the Division of Haematology/Oncology at Meharry Medical College, Nashville, TN.
  • Bradley J. Monk: Professor in the Department of Obstetrics and Gynaecology, Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ.
  • Igor Puzanov: Associate Professor of Medicine in the Division of Haematology-Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN.

KOLs from Europe

  • Anonymous German KOL: This physician specialises in haematology, oncology and tumour immunology.
  • Mark Drummond: Lead Clinician, Blood Cancers, West of Scotland Managed Clinical Network for Haemato-Oncology, NHS Greater Glasgow and Clyde.
  • Rebecca Kristeleit: Consultant Medical Oncologist, North London Gynaecological Cancer Network, University College London, UK.
  • Alberto Ocaña: Director of Translational Cancer Research Unit, Albacete University Hospital, Spain.
  • Sheila Piva: Consultant Oncologist, Department of Oncology, Fatebenefratelli e Oftalmico, Milan, Italy.
  • Ayhan Ulusakarya: Consultant Physician, Medical Oncology, Paul Brousse Hospital, Paris, France.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Back to Top